Back to Search
Start Over
Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: A phase II trial.
- Source :
-
International Journal of Urology . Mar2002, Vol. 9 Issue 3, p162-166. 5p. - Publication Year :
- 2002
-
Abstract
- Abstract Background : A phase II multicentric trial of paclitaxel and cisplatin was conducted in previously untreated patients, with locally advanced transitional-cell carcinoma (TCC) of the bladder, to assess its toxicity and efficiency in preserving the bladder. Methods : Forty-four patients with locally advanced TCC of the bladder (seven with T3a, 27 with T3b, and eight with T4a) were treated with paclitaxel 175 mg/m 2 over 3 h, and cisplatin 75 mg/m 2 over 30 min, on the first day of each 21-day treatment cycle. Therapy was continued for three cycles. Patients were re-evaluated and scheduled for radiotheraphy or radical surgery depending on tumoral response. Tumoral response was measured by citology, computed tomographical scans, and deep randomized biopsies of the bladder. Results : Thirty-two out of 42 patients (76%; 95% confidence interval 45–93%) showed a major response (22 complete, and 10 partial). Response times ranged from 18 to 54 months. Three patients with T4 bladder primary tumors experienced a pathological CR. At a median follow-up of three years, 20 patients remain free of disease (47.6%), six patients are alive with disease (14.3%), 12 patients died of disease (28.5%), and four others died of unrelated causes (9.5%). Hematological toxicity included anemia, thrombocytopenia, and neutropenia. No grade four febrile neutropenia was observed. Non-hematological toxicity included alopecia (93.2%), diarrhea (11.4%), vomiting (18.5%) mucosytis (4.6%), and neuropathy (4.6%). Drug omissions or dose delay for adverse events were only necessary in one patient (2.2%), and three patients (6.8%), respectively. Conclusions : Paclitaxel and cisplatin is an active and well-tolerated neo-adjuvant regimen for previously untreated patients with pure TCC of the bladder, achieving a vesical preservation rate of 52%. [ABSTRACT FROM AUTHOR]
- Subjects :
- *BLADDER cancer
*PACLITAXEL
*CISPLATIN
Subjects
Details
- Language :
- English
- ISSN :
- 09198172
- Volume :
- 9
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- International Journal of Urology
- Publication Type :
- Academic Journal
- Accession number :
- 6692042
- Full Text :
- https://doi.org/10.1046/j.1442-2042.2002.00443.x